文献速递骨质疏松与代谢性骨病小儿骨科

双膦酸盐治疗儿童、青少年及年轻成人继发性骨质疏松:系统综述与荟萃分析

Bisphosphonate treatment for secondary osteoporosis in children, youth, and young adults: a systematic review and meta-analysis.
PubMed 文献 · Osteoporos Int · 2026-01-27

荟萃分析显示双膦酸盐改善腰椎骨密度z评分(均差0.67;95%CI 0.37, 0.97)和腰椎骨矿物含量(均差2.90 g;95%CI 0.91, 4.90),但无足够把握度的研究评估骨折,不良事件在治疗组与对照组间相当(RR 1.08;95%CI 0.94, 1.23),仅首次输注后短期不良事件更常见(RR 2.24;95%CI 1.22, 4.11)。

要点

  • 双膦酸盐可改善≤21岁继发性骨质疏松患者腰椎骨密度z评分和骨矿物含量。
  • 无足够把握度的研究评估椎体或非椎体骨折,患者报告结局结果不一致。
  • 总体不良事件与对照组相当,但首次输注后短期不良事件风险增加。

核心结论

  • 双膦酸盐治疗通过改善腰椎骨密度和骨矿物含量使儿童继发性骨质疏松患者获益,但样本量小和方法异质性影响结果可靠性,需更大规模随机对照试验评估骨折率。

研究设计与样本

  • 系统综述与荟萃分析,检索Ovid MEDLINE、EMBASE、PubMed、Web of Science、CINAHL和Cochrane CENTRAL至2025年5月29日,遵循PRISMA和GRADE方法,注册于PROSPERO(CRD42021242156)。

主要发现

  • 双膦酸盐改善腰椎骨密度z评分(均差0.67;95%CI 0.37, 0.97)和腰椎骨矿物含量(均差2.90 g;95%CI 0.91, 4.90)。
  • 无足够把握度的研究评估椎体和非椎体骨折,患者报告结局结果不一致。
  • 不良事件在治疗组与对照组间相当(RR 1.08;95%CI 0.94, 1.23),但首次输注后短期不良事件治疗组更可能发生(RR 2.24;95%CI 1.22, 4.11)。

关键数值与推荐

  • 腰椎骨密度z评分均差0.67(95%CI 0.37, 0.97),腰椎骨矿物含量均差2.90 g(95%CI 0.91, 4.90)。
  • 不良事件相对风险1.08(95%CI 0.94, 1.23),首次输注后短期不良事件相对风险2.24(95%CI 1.22, 4.11)。

临床怎么用

  • 对于≤21岁继发性骨质疏松患者,双膦酸盐可考虑用于改善腰椎骨密度和骨矿物含量。
  • 需关注首次输注后短期不良事件风险增加,并告知患者相关风险。
  • 骨折预防的获益尚未经足够把握度的研究证实,临床决策需结合个体情况。

局限性

  • 纳入研究样本量小且方法异质性大,影响结果可靠性。
  • 无足够把握度的研究评估骨折率,需更大规模随机对照试验。
  • 患者报告结局结果不一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic illnesses and their treatments in childhood pose significant risks of bone fragility due to osteoporosis. Bisphosphonates (BP) are commonly used for treatment, yet evidence remains limited and heterogeneous. This systematic review aims to consolidate current empirical evidence on BP efficacy and safety in children, youth and young adults aged ≤ 21 years with secondary osteoporosis. Ovid MEDLINE and EMBASE, PubMed, Web of Science, Cumulative Index to Nursing and Allied Health, and Cochrane Central Register of Controlled Trials were searched by May 29th, 2025. This review followed the PRISMA guidelines the GRADE approach. This review was registered at PROSPERO (CRD42021242156). Seventeen studies were included (fifteen randomized controlled trials (RCTs), two quasi-RCTs) evaluating BP. Meta-analysis indicated that BP improved lumbar spine bone mineral density (BMD) z-score (mean difference (MD): 0.67; 95% confidence interval (CI): 0.37, 0.97) and lumbar spine bone mineral content (BMC) (MD: 2.90 g; 95% CI: 0.91, 4.90). There were no studies adequately powered to assess vertebral and non-vertebral fractures. Patient-reported outcomes showed no consistent results. Adverse events (AEs) were comparable between treatment and control groups (relative risk (RR): 1.08; 95% CI: 0.94, 1.23). When limited to short-term periods after the first infusion, AEs were more likely in the treatment group (RR: 2.24; 95% CI: 1.22, 4.11). BP treatment benefits pediatric secondary osteoporosis by improving lumbar spine BMD and BMC. However, small sample sizes and heterogeneity among the study methods continue to challenge the reliability of results, and larger RCTs are needed to assess fracture rates.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Kim H, Yao X, Li O, et al. Bisphosphonate treatment for secondary osteoporosis in children, youth, and young adults: a systematic review and meta-analysis. Osteoporos Int. 2026. PMID: 41591403. doi:10.1007/s00198-025-07837-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。